Gordon Freeman, Ph.D.
Dr. Freeman is a Professor of Medical Oncology at the Dana-Farber Cancer Institute. His laboratory studies the contribution of costimulatory signals to the immune response. Following the discovery of PD-L1 and PD-L2 as the ligands for the PD-1 receptor on T cells, the Freeman Lab demonstrated their inhibitory function on T cells and showed that the blockade of this pathway enhanced T cell activation, proliferation, and cytokine production. Further studies showed that PD-L1 is highly expressed by many solid tumors/hematological malignancies, and that the blockade of PD-L1 enhances killing of PD-L1 positive targets by CD8 T cells. Recently, PD-1 blocking antibodies were approved by the FDA for the treatment of melanoma and lung cancer.
Dr. Freeman received his Ph.D. from Harvard University and also joined DFCI that year. He did postdoctoral training in the laboratory of Dr. Harvey Cantor and then with Dr. Lee Nadler.
Scott joined iTeos as Chief Scientific Officer in July 2018. Prior to this, he was the Chief Technology Officer at Surface Oncology. At Surface, Scott oversaw all antibody generation, engineering, production and protein characterization. He also managed all preclinical IND enabling studies and GMP manufacturing of antibodies. Scott is an accomplished scientist who directed research that has led to the development of several FDA-approved and marketed biological products.
Scott joined Surface from Arteaus Therapeutics (acquired by Eli Lilly in 2014) where he was co-founder and Chief Scientific Officer. Prior to Arteaus, Scott was a Founder and Chief Scientific Officer of Tokai Pharmaceuticals, where he worked to develop an oral therapeutic for prostate cancer. Scott has also held positions as Senior Vice President of Research at Dyax, identifying therapeutic antibodies using phage display, and as Chief Scientist at Serono.
Scott received his PhD in Neuroscience from the University of Maryland School of Medicine. He has authored or co-authored more than 65 peer-reviewed scientific publications and been named inventor on 19 issued U.S. patents.
Pierre Coulie, M.D., Ph.D.
Prof. Pierre G. Coulie is a Professor at the Faculty of Medicine of the Université Catholique de Louvain (UCL). Trained in immunology as a student by Prof. Jacques Van Snick, he worked on murine rheumatoid factors and cytokines. In 1988, he joined the group of Prof. Thierry Boon and switched to human immunology. As investigator at the Brussels branch of the Ludwig Institute for Cancer Research from 1989 to 1995, he made important contributions to the identification of human tumor-specific antigens recognized by T lymphocytes. Pursuing his collaboration with the neighboring teams of the Ludwig Institute, his current work is focused on human anti-tumor immunology in the context of therapeutic vaccination using tumor-specific antigens His work specifically aims to understand the mechanisms of tumor regression observed in some vaccinated melanoma patients, and the reasons for clinical vaccine failure in most patients.
William Hahn, M.D., Ph.D.
Dr. Hahn is a Professor of Medicine, Medical Oncology at the Dana-Farber Cancer Institute as well as the Chair of the Executive Committee for Research in Oncology at the Dana-Farber. His work as a physician-scientist involves both the care of cancer patients and biomedical research directed toward a greater understanding of the mechanisms involved in malignant transformation. His laboratory focuses on understanding the cooperative interactions that conspire to transform human cells. Dr. Hahn received his M.D. and Ph.D. from Harvard Medical School in 1994. He completed his clinical training in internal medicine at Massachusetts General Hospital and in medical oncology at DFCI. Dr. Hahn conducted his postdoctoral studies with Dr. Robert Weinberg at the Whitehead Institute and joined the faculty of DFCI and Harvard Medical School in 2001.
Ben Stanger, M.D., Ph.D.
Dr. Stanger is a Professor of Medicine at the University of Pennsylvania Perelman School of Medicine. His laboratory studies cellular plasticity in the context of epithelial-to-mesenchymal transition that promotes cell invasion and metastasis. His laboratory has a strong interest in tumor immunology, and the mechanisms by which tumor cells influence their microenvironment. The ability to manipulate cellular identity in these settings will facilitate the development of novel therapies for cancer and degenerative disease. Dr Stanger received a SB (Life Sciences) from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a Ph.D. (Genetics) from Harvard Medical School.
Benoît Van den Eynde, M.D., Ph.D.
Prof. Benoit Van den Eynde is a co-founder of iTeos Therapeutics. He is the Director of Ludwig Cancer Research Brussels since 2010. He also holds the positions of Professor at UCLouvain, Brussels, Director of the de Duve Institute in Brussels, and Professor of Tumour Immunology at the University of Oxford. He is a recognized expert in tumor immunology, a field to which he contributed in the early nineties by identifying some of the very first tumor antigens recognized by CD8+ T lymphocytes. His analyses of the processing of tumor antigens led to the discovery of peptide splicing by the proteasome, and the identification of new proteasome subtypes. His group was also the first to demonstrate that many tumors express the enzymes indoleamine dioxygenase or tryptophan dioxygenase, which suppress T lymphocyte activity by locally depleting tryptophan in the microenvironment. His current research focuses on immunosuppressive mechanisms in the tumor microenvironment.
Benoit holds a medical degree and a Ph.D. in immunology from UCLouvain. He has authored more than 180 peer-reviewed publications and been named inventor on 32 US patents. He has received several awards during his career, including the 2007 GlaxoSmithKline Prize and the Joseph Maisin Prize in Biomedical Sciences.
Matt Vander Heiden, M.D., Ph.D.
Dr. Vander Heiden is an Associate Professor of Biology and an Associate Director at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. He is a practicing oncologist and instructor in medicine at Dana-Farber Cancer Institute/Harvard Medical School. He earned his doctoral and medical degrees from the University of Chicago, where he worked in the laboratory of Craig Thompson. Dr. Heiden then completed a residency in internal medicine at Boston’s Brigham & Women’s Hospital and a hematology-oncology fellowship at Dana-Farber Cancer Institute/Massachusetts General Hospital. He was a post-doctoral fellow in the laboratory of Lewis Cantley at Harvard Medical School, where he was supported by a Mel Karmazin Fellowship from the Damon Runyon Cancer Research Foundation. In 2010, Dr. Heiden joined the MIT faculty. His work has been recognized by many awards including the Burroughs Wellcome Fund Career Award for Medical Sciences, the AACR Gertrude B. Elion Award, the HHMI Faculty Scholar Award, and the Stand Up To Cancer Phillip A. Sharp Innovation in Collaboration Award.